ライフサイエンスコーパス: ziprasidone

1 idepressant efficacy also favored adjunctive ziprasidone.

2 ne, olanzapine, quetiapine, risperidone, and ziprasidone.

3 efficacy versus haloperidol, quetiapine, and ziprasidone.

4 ment, in patients treated with quetiapine or ziprasidone.

5 eridone, and 79 percent of those assigned to ziprasidone.

6 ilar to that of quetiapine, risperidone, and ziprasidone.

7 these variables were significant and favored ziprasidone.

8 r other safety parameters were observed with ziprasidone.

9 ped antipsychotic drugs, e.g., clozapine and ziprasidone.

10 liorated by clozapine but not haloperidol or ziprasidone.

11 -0.14), olanzapine (-0.25, -0.39 to -0.12), ziprasidone (-0.25, -0.48 to -0.01), and risperidone (-0

12 14.0 [6.0-18.0] days) as did patients in the ziprasidone (15.0 [9.1-18.0] days) and placebo groups (1

13 onths) than with quetiapine (4.0 months) and ziprasidone (2.8 months).

14 , quetiapine=125, risperidone=124, UC=30 and ziprasidone=32), 4 of which were conference abstracts an

15 Ziprasidone (40 to 160 mg per day) was included after it

16 io to 3 weeks of double-blind treatment with ziprasidone (40-80 mg twice daily) or placebo.

17 =63]; risperidone, 1.5-6.0 mg/day [N=69]; or ziprasidone, 40-160 mg/day [N=135]).

18 ne, quetiapine, olanzapine, risperidone, and ziprasidone all potently antagonize the beta-arrestin 2

19 antly increased with olanzapine but not with ziprasidone; all between-group comparisons of these vari

20 mean daily doses were 129.9 mg (SD=27.3) for ziprasidone and 11.3 mg (SD=2.8) for olanzapine.

21 During 6 weeks' treatment, ziprasidone and olanzapine demonstrated comparable antip

22 pared 1-year mortality rates associated with ziprasidone and olanzapine in real-world use.

23 rs compared the efficacy and tolerability of ziprasidone and olanzapine in the treatment of acutely i

24 le and CGI severity scale scores between the ziprasidone and placebo groups.

25 gs (olanzapine, quetia-pine, risperidone, or ziprasidone) and followed for up to 18 months.

26 n, including thioridazine, mesoridazine, and ziprasidone, and for monitoring for signs of myocarditis

27 apine was more effective than quetiapine and ziprasidone, and risperidone was more effective than que

28 66 risperidone, olanzapine, quetiapine, and ziprasidone arms including 7264 patients.

29 Ziprasidone as an adjunct to escitalopram demonstrated a

30 pine were more effective than quetiapine and ziprasidone as reflected by longer time until discontinu

31 idone, olanzapine, quetiapine, aripiprazole, ziprasidone, asenapine, iloperidone, or paliperidone) wi

32 y evaluated the efficacy and tolerability of ziprasidone, compared with placebo, in the treatment of

33 Ziprasidone does prolong the QT interval, but there is n

34 ssigned in a 1:1 ratio to receive adjunctive ziprasidone (escitalopram plus ziprasidone, N=71) or adj

35 e, perphenazine, quetiapine, risperidone, or ziprasidone for up to 18 months.

36 The escitalopram plus ziprasidone group also showed significantly greater impr

37 sia, compared with six (20%) patients in the ziprasidone group and seven (19%) patients in the placeb

38 Ten (14%) patients in the escitalopram plus ziprasidone group discontinued treatment because of into

39 nificantly greater for the escitalopram plus ziprasidone group.

40 ne, quetiapine, olanzapine, risperidone, and ziprasidone, have been reported to preferentially increa

41 Ziprasidone hydrochloride was included after its approva

42 rs sought to test the efficacy of adjunctive ziprasidone in adults with nonpsychotic unipolar major d

43 red olanzapine, quetiapine, risperidone, and ziprasidone in patients who had just discontinued a diff

44 with olanzapine, quetiapine, risperidone, or ziprasidone in phase 1 or 1B of the trials, primarily be

45 e findings of this study failed to show that ziprasidone is associated with an elevated risk of nonsu

46 Only widespread use will prove if ziprasidone is entirely safe.

47 Ziprasidone, like many BCS Class II drugs with low intri

48 Ziprasidone monotherapy was significantly superior to pl

49 , patients were randomly assigned to receive ziprasidone (N=136) or olanzapine (N=133).

50 r of initiating pharmacotherapy was 0.91 for ziprasidone (N=9,077) and 0.90 for olanzapine (N=9,077).

51 ve adjunctive ziprasidone (escitalopram plus ziprasidone, N=71) or adjunctive placebo (escitalopram p

52 The Ziprasidone Observational Study of Cardiac Outcomes (ZOD

53 apine (odds ratio: 1.56, 95% CI: 1.47-1.67), ziprasidone (odds ratio: 1.40, 95% CI: 1.19-1.65), and f

54 , N=386), amisulpride (one study, N=331), or ziprasidone (one study, N=207) for a weighted mean and m

55 ly assigned to receive treatment with either ziprasidone or olanzapine and followed for 1 year by unb

56 randomly assigned to receive haloperidol or ziprasidone or placebo every 6 hrs for up to 14 days.

57 , the risk was higher among those initiating ziprasidone (OR, 1.61; 95% CI, 0.99-2.64; P = .06) and a

58 0.26 for risperidone (P<.001), and 0.12 for ziprasidone (P<.06), with no significant differences bet

59 up, but not in the perphenazine (P=0.021) or ziprasidone (P=0.028) group.

60 Ziprasidone produced rapid, sustained improvements relat

61 e.g. clozapine, risperidone, olanzapine and ziprasidone, to improve cognitive function in schizophre

62 pite the known risk of QTc prolongation with ziprasidone treatment, the findings of this study failed

63 Quetiapine, risperidone, and ziprasidone use were not associated with the warning.

64 lafaxine, bupropion, quetiapine, olanzapine, ziprasidone, valproic acid, carbamazepine, and citalopra

65 der adults with schizophrenia, intramuscular ziprasidone was found to be effective, and evidence is e

66 set of action was rapid, and tolerability of ziprasidone was generally comparable to that of placebo.

67 Ziprasidone was well tolerated and associated with a low

68 Olanzapine, but not ziprasidone, was associated with significant increases i

69 Differences favoring ziprasidone were observed in metabolic parameters.

70 long-acting injection (risperidone LAI), and ziprasidone--were used to identify a cohort of 24 FDA-re